Trial Profile
Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting the Tumor-associated Antigens NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE in Patients With Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs BNT 111 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Acronyms Lipo-MERIT
- Sponsors BioNTech
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 12 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jun 2023.
- 12 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 Jun 2023.